Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR

Eagle Health Investments LP purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 166,148 shares of the company's stock, valued at approximately $19,052,000. Kymera Therapeutics comprises approximately 3.2% of Eagle Health Investments LP's investment portfolio, making the stock its 14th largest holding. Eagle Health Investments LP owned 0.20% of Kymera Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after buying an additional 98 shares during the period. Smartleaf Asset Management LLC grew its stake in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the 4th quarter valued at $63,000. Finally, Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the period.

Kymera Therapeutics Stock Up 4.9%

KYMR stock opened at $127.31 on Thursday. The company has a market cap of $10.59 billion, a price-to-earnings ratio of -39.29 and a beta of 1.95. The business has a fifty day simple moving average of $107.98 and a 200-day simple moving average of $91.49. Kymera Therapeutics, Inc. has a 52 week low of $39.84 and a 52 week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million for the quarter, compared to analysts' expectations of $32.78 million. During the same quarter last year, the firm earned ($0.95) earnings per share. The firm's revenue for the quarter was up 465.2% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 80,000 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the completion of the sale, the chief executive officer owned 666,568 shares in the company, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares of the company's stock, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,604,813 shares of company stock valued at $387,557,004. 15.98% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Brookline Capital Markets reaffirmed a "buy" rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Citigroup reiterated a "buy" rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Truist Financial raised their price target on Kymera Therapeutics from $116.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Barclays upped their price objective on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Finally, B. Riley Financial increased their price objective on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Twenty investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $125.65.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source